New York, New York–(Newsfile Corp. – December 28, 2024)– Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Kyverna Therapeutics, Inc.'s common stock. (NASDAQ: KYTX) pursuant to and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the “IPO”), it is important February 7, 2025 Lead Plaintiff Deadline.
so what: If you purchase Kyverna common stock, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Kyverna class action, go to https://rosenlegal.com/submit-form/?case_id=32239 or contact Phillip Kim, Esq. Toll free is 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court No later than February 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the lawsuit.
Why Rosen's Law: We encourage investors to select qualified advisors with a proven track record of success in leadership roles. Often, companies issuing notices do not have similar experience, resources, or any meaningful recognition from their peers. Many of these firms do not actually file securities class actions, but are merely brokers who refer clients or partner with the law firms that actually file the lawsuits. Be wise in choosing advisors. The Rosen Law Firm represents investors throughout the world, focusing its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever settlement of a securities class action lawsuit against a Chinese company at that time. Rosen Law Firm is Ranked #1 by ISS Securities Class an act (WA:) Services for a number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company raised more than $438 million for investors. In 2020, co-founder Lawrence Rosen was named by Law360 as a Titan in the Plaintiffs Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Case details: According to the lawsuit, the registration statement and prospectus used to effectuate Kyverna's initial public offering contained false and/or omitted facts relating to the results of Kyverna's ongoing evaluation of KYV-101, Kyverna's lead product candidate, in clinical trials. Specifically, Kyverna touted patient “improvement” in certain indications while failing to disclose negative data related to one of Kyverna's trials, which Kyverna was known to at the time of the IPO. When the true details entered the market, the lawsuit claims, investors suffered damages.
To join the Kyverna class action, go to https://rosenlegal.com/submit-form/?case_id=32239 or contact Phillip Kim, Esq. Toll free is 866-767-3653 or email case@rosenlegal.com for information about the class action.
No category is approved. Until the class is approved, you will not be represented by counsel unless you retain one. You can choose the lawyer of your choice. You can also remain an absent class member and do nothing at this point. An investor's ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https: //www.facebook.com/rosenlawfirm/.
Lawyer advertisement. Previous results do not guarantee a similar result.
——————————-
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235359
